- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00893451
Study of Vitamin D3 Supplementation in Patients With Chronic Kidney Disease (VitaD-CKD1)
Does Vitamin D3 (Cholecalciferol) Supplementation Change Insulin Resistance in Patients With Chronic Kidney Disease?
Study Overview
Status
Intervention / Treatment
Detailed Description
Insulin resistance, i.e., reduction in insulin responsiveness with a decrease in glucose uptake in insulin target tissues (muscle and adipose tissue) is common in end-stage renal disease (ESRD), but is also present at earlier stages of renal disease with mild-moderate renal function impairment as well as in microalbuminuria and nephrotic syndrome.
Population-based cross-sectional studies have shown that low levels of vitamin D (25(OH) vitamin D) is associated with impaired glucose tolerance in subjects with normal renal function and that reduced renal function and 25(OH) vitamin D deficiency are independently associated with insulin resistance.
Vitamin D has well-known effects on calcium metabolism and skeletal mineralisation but recent experimental studies suggest that vitamin D in addition reduces several inflammatory mediators that are of importance in the development and progression of renal disease which also associated with insulin resistance such as TNF-α and IL-6.
This is a prospective, single-blind, explorative, randomized, placebo-controlled, single-centre, two-way cross-over study with two treatment periods of 10 weeks separated by a washout period of 6 weeks. Non-diabetic patients with chronic kidney disease (CKD) stage 3 and 4 (GFR 15-60 ml/min/1.73m2) who have low serum 25-OH-vitamin D levels (< 30 ng/mL) and elevated fasting serum insulin levels (>10 IU/L) will be randomized to receive either vitamin D3 (cholecalciferol) 3200U orally (tablets) daily or placebo.
Approximately 24 patients are going to complete the study. A pre-entry wash-out period of 6 weeks is needed for patents already on vitamin D treatment. An in vivo assessment of insulin secretion and insulin sensitivity will be made by insulin-glucose clamp at the end of each treatment period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gothenburg, Sweden, 41345
- Department of Kidney diseases, Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age older than 18 years
- Non-diabetic chronic kidney disease stage 3 and 4 (GFR 15-60 ml/min/1.73 m2)
- Serum 25(OH) vitamin D < 30 ng/mL (75 nmol/L)
- Fasting S-insulin > 30 IU/L
- Written informed consent before entered into study
Exclusion Criteria:
- Patients with current significant, major or unstable cardio-cerebrovascular, infection, respiratory, gastrointestinal or other major disease and risks according to the judgment made by the investigator
- Patients with type 1 or type 2 Diabetes
- Current severe thyrotoxicosis or other endocrine disease
- Granulomatous disease, such as sarcoidosis and tuberculosis
- Patients who are intended to receive hemodialysis (HD), peritoneal dialysis (PD) or being kidney transplanted during the course of study (9 months)
- Concomitant use of corticosteroids (except for inhalation or topical use) or other immunosuppressive medication
- Treatment with biphosphonate during last two years
- S-Calcium > 2.70 mmol/L (0.68 mg/dl)
- PTH intact < 75 ng/L (8.25 nmol/L) or > 800 ng/L (88 nmol/L)
- Proteinuria > 3.5 g/24 hours
- Alcohol or drug abuse or any condition associated with poor compliance
- Blood donors
- Women of childbearing potential, desired pregnancy, pregnancy or lactation within the study period
- Allergy or intolerance to cholecalciferol supplementation (TillVal D®) or other constituents
- Participation in a clinical trial evaluating an investigational drug in the last 12 weeks prior to inclusion to this trial
- History of kidney stones
- History of chronic hepatitis or liver enzymes (ASAT or ALAT) more than 2.5 times the upper limit of normal
- Gastrointestinal disease resulting in significant gastrointestinal dysfunction or malabsorption
- Use of medications known to interact with vitamin D metabolism such as cholestyramine, phenytoin, digitalis and antacids
- Planned vacation with "high sun exposure" during the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
Vitamin D3 1600 IU orally twice daily
|
In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
Other Names:
|
Placebo Comparator: B
Placebo orally twice daily
|
Placebo orally twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in M-value (mg/kg lean body mass/min) assessed by insulin-glucose clamp
Time Frame: at week 26
|
at week 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in systolic- and diastolic blood pressure
Time Frame: at week 26
|
at week 26
|
Change in PTH secretion and its fragments assessed by PTH, CAP-PTH, CIP-PTH
Time Frame: at week 26
|
at week 26
|
Change in insulin secretion assessed by intravenous glucose tolerance test
Time Frame: at week 26
|
at week 26
|
Change in urinary excretion of albumin (UAE) assessed by 24 hour collection
Time Frame: at week 26
|
at week 26
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hamid R Dezfoolian, MD, Sahlgrenska University Hospital, Sweden
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Renal Insufficiency
- Nutrition Disorders
- Hyperinsulinism
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Kidney Diseases
- Renal Insufficiency, Chronic
- Vitamin D Deficiency
- Insulin Resistance
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- VitaD-CKD1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
University Hospital, Clermont-FerrandTerminated
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Okan UniversityArçelik A.Ş.Completed
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
Clinical Trials on cholecalciferol (TillVal-D)
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
Centre of Postgraduate Medical EducationUnknownInfant, Premature, DiseasesPoland
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Wayne State UniversityNovartisUnknown
-
Hospices Civils de LyonUnknown
-
Organon and CoCompleted
-
Mansoura University Children HospitalCompletedPrematurity | Late-onset SepsisEgypt
-
McGill UniversityCompleted
-
Bumi HermanCompleted
-
VA Office of Research and DevelopmentCompleted